MX2017002856A - Anticuerpos siglec de reaccion cruzada. - Google Patents

Anticuerpos siglec de reaccion cruzada.

Info

Publication number
MX2017002856A
MX2017002856A MX2017002856A MX2017002856A MX2017002856A MX 2017002856 A MX2017002856 A MX 2017002856A MX 2017002856 A MX2017002856 A MX 2017002856A MX 2017002856 A MX2017002856 A MX 2017002856A MX 2017002856 A MX2017002856 A MX 2017002856A
Authority
MX
Mexico
Prior art keywords
cross reactive
siglec antibodies
reactive siglec
agents
antibodies
Prior art date
Application number
MX2017002856A
Other languages
English (en)
Inventor
Cornen Stéphanie
Rossi Benjamin
Wagtmann Nicolaï
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54072835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017002856(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of MX2017002856A publication Critical patent/MX2017002856A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Esta invención se refiere a agentes que enlazan múltiples Siglecs, incluyendo anticuerpos que neutralizan la actividad inhibidora de múltiples Siglec-7 y Siglec-9 en linfocitos. Tales agentes pueden usarse para el tratamiento de cánceres o enfermedades infecciosas.
MX2017002856A 2014-09-10 2015-09-09 Anticuerpos siglec de reaccion cruzada. MX2017002856A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048292P 2014-09-10 2014-09-10
PCT/EP2015/070550 WO2016038064A1 (en) 2014-09-10 2015-09-09 Cross reactive siglec antibodies

Publications (1)

Publication Number Publication Date
MX2017002856A true MX2017002856A (es) 2017-05-30

Family

ID=54072835

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002856A MX2017002856A (es) 2014-09-10 2015-09-09 Anticuerpos siglec de reaccion cruzada.

Country Status (8)

Country Link
US (1) US20170306014A1 (es)
EP (1) EP3191517B1 (es)
JP (2) JP2017532025A (es)
AU (1) AU2015314316B2 (es)
CA (1) CA2957351A1 (es)
DK (1) DK3191517T3 (es)
MX (1) MX2017002856A (es)
WO (1) WO2016038064A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016038064A1 (en) 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies
EP3325967B1 (en) 2015-07-24 2019-12-04 Innate Pharma Methods for detecting tissue infiltrating nk cells
CN115960235A (zh) 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
CA3003458A1 (en) * 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
AU2016354924A1 (en) 2015-11-17 2018-06-21 Innate Pharma Siglec-10 antibodies
AU2017207807A1 (en) * 2016-01-12 2018-07-12 Palleon Pharmaceuticals Inc. Use of Siglec-7 or Siglec-9 antibodies for the treatment of cancer
US11078274B2 (en) * 2016-03-08 2021-08-03 Innate Pharma Siglec neutralizing antibodies
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
GB201611535D0 (en) * 2016-07-01 2016-08-17 King's College London Methods and compositions for treating cancer with siglec-9 activity modulators
WO2018006034A1 (en) 2016-07-01 2018-01-04 The Board Of Trustees Of The Leland Stanford Junior University Conjugates for targeted cell surface editing
CA3026588A1 (en) * 2016-07-01 2018-01-04 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory immune receptor inhibition methods and compositions
JP7137563B2 (ja) * 2016-08-05 2022-09-14 アラコス，インコーポレイティド がん治療用の抗Ｓｉｇｌｅｃ－７抗体
CN106831989A (zh) * 2017-01-04 2017-06-13 中国人民解放军南京军区军事医学研究所 人源抗唾液酸结合免疫球蛋白样凝集素‑7的抗体IgG及其应用
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2019011855A1 (en) * 2017-07-10 2019-01-17 Innate Pharma ANTIBODIES NEUTRALIZING SIGLEC-9
EP3652207A1 (en) * 2017-07-10 2020-05-20 Innate Pharma Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer
CA3070297A1 (en) * 2017-08-11 2019-02-14 Genentech, Inc. Anti-cd8 antibodies and uses thereof
US10927180B2 (en) 2017-10-13 2021-02-23 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
CN112135904A (zh) 2018-01-03 2020-12-25 帕利昂制药有限公司 重组人唾液酸酶、唾液酸酶融合蛋白及其使用方法
US11912766B2 (en) 2018-01-11 2024-02-27 Allakos, Inc. Anti-Siglec-7 antibodies having reduced effector function
EP3802582A4 (en) * 2018-06-07 2022-06-15 Palleon Pharmaceuticals Inc. MULTIMERIC PROTEINS FOR DETECTING A CARBOHYDRATE AND/OR TREATMENT OF A SIGLEC MEDIATED DISORDER
EP3801767A1 (en) * 2018-06-08 2021-04-14 Alector LLC Anti-siglec-7 antibodies and methods of use thereof
KR20210086623A (ko) 2018-09-25 2021-07-08 하푼 테라퓨틱스, 인크. Ddl3 결합 단백질 및 사용 방법
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AU2020378251A1 (en) 2019-11-04 2022-05-26 Alector Llc Siglec-9 ECD fusion molecules and methods of use thereof
EP4172188A1 (en) * 2020-06-30 2023-05-03 The Board of Trustees of the Leland Stanford Junior University Cis-binding siglec agonists and related compositions and methods
JP2023532768A (ja) 2020-07-07 2023-07-31 バイオエヌテック エスエー Ｈｐｖ陽性癌の治療用ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
KR20240046323A (ko) 2021-07-13 2024-04-08 비온테크 에스이 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002326531A1 (en) * 2001-08-03 2003-02-17 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
JP2006265155A (ja) * 2005-03-23 2006-10-05 Link Genomics Kk 癌の免疫療法
WO2014120642A1 (en) * 2013-01-30 2014-08-07 The General Hospital Corporation Diagnosis and treatment of hepatorenal syndrome
WO2016038064A1 (en) 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies

Also Published As

Publication number Publication date
DK3191517T3 (da) 2021-01-25
CA2957351A1 (en) 2016-03-17
EP3191517B1 (en) 2020-11-04
JP2017532025A (ja) 2017-11-02
AU2015314316B2 (en) 2020-12-10
AU2015314316A1 (en) 2017-03-09
JP2022109920A (ja) 2022-07-28
US20170306014A1 (en) 2017-10-26
WO2016038064A1 (en) 2016-03-17
EP3191517A1 (en) 2017-07-19

Similar Documents

Publication Publication Date Title
MX2017002856A (es) Anticuerpos siglec de reaccion cruzada.
JOP20200192A1 (ar) أجسام مضادة لـ tigit
PH12016501456A1 (en) Antibody molecules to pd-1 and uses thereof
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
PH12017500692A1 (en) Antibody molecules to pd-l1 and uses thereof
PH12017500803A1 (en) Anti-pd-1 antibodies
JO3567B1 (ar) جزيئات جسم مضاد لـ tim-3 واستخداماتها
HK1247848A1 (zh) 抗pd-1和抗m-csf抗體在治療癌症中的聯合應用
WO2015116868A3 (en) Molecular profiling of immune modulators
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
WO2015185875A9 (fr) Anticorps dirigé contre la galectine 9 et inhibiteur de l'activité suppressive des lymphocytes t régulateurs
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
ZA201706402B (en) C.novyi for the treatment of solid tumors in humans
MX2017002323A (es) Variantes de desintegrina y usos farmaceuticos de las mismas.
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
TN2017000201A1 (en) Use of sigma receptor ligands in osteoarthritis
TH1601001559A (th) สารเชิงซ้อนที่มีโอลิโกนิวคลีโอไทด์ที่มีแอคทิวิตีการเสริมฤทธิ์ทางอิมมูน และการใช้ของมัน
GB201408854D0 (en) Processing transactions using multiple financial sources
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes